146 related articles for article (PubMed ID: 9516958)
1. Preclinical evaluation of 5-iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyuridine-mediated radiosensitization in mouse and human tissues.
Kinsella TJ; Kunugi KA; Vielhuber KA; Potter DM; Fitzsimmons ME; Collins JM
Clin Cancer Res; 1998 Jan; 4(1):99-109. PubMed ID: 9516958
[TBL] [Abstract][Full Text] [Related]
2. Preclinical toxicity and efficacy study of a 14-day schedule of oral 5-iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyuridine radiosensitization in U251 human glioblastoma xenografts.
Kinsella TJ; Vielhuber KA; Kunugi KA; Schupp J; Davis TW; Sands H
Clin Cancer Res; 2000 Apr; 6(4):1468-75. PubMed ID: 10778979
[TBL] [Abstract][Full Text] [Related]
3. An in vivo comparison of oral 5-iodo-2'-deoxyuridine and 5-iodo-2-pyrimidinone-2'-deoxyribose toxicity, pharmacokinetics, and DNA incorporation in athymic mouse tissues and the human colon cancer xenograft, HCT-116.
Kinsella TJ; Kunugi KA; Vielhuber KA; McCulloch W; Liu SH; Cheng YC
Cancer Res; 1994 May; 54(10):2695-700. PubMed ID: 8168099
[TBL] [Abstract][Full Text] [Related]
4. Schedule-dependent drug effects of oral 5-iodo-2-pyrimidinone-2'-deoxyribose as an in vivo radiosensitizer in U251 human glioblastoma xenografts.
Seo Y; Yan T; Schupp JE; Radivoyevitch T; Kinsella TJ
Clin Cancer Res; 2005 Oct; 11(20):7499-507. PubMed ID: 16243824
[TBL] [Abstract][Full Text] [Related]
5. Preclinical study of the systemic toxicity and pharmacokinetics of 5-iodo-2-deoxypyrimidinone-2'-deoxyribose as a radiosensitizing prodrug in two, non-rodent animal species: implications for phase I study design.
Kinsella TJ; Schupp JE; Davis TW; Berry SE; Hwang HS; Warren K; Balis F; Barnett J; Sands H
Clin Cancer Res; 2000 Sep; 6(9):3670-9. PubMed ID: 10999760
[TBL] [Abstract][Full Text] [Related]
6. Differential radiosensitization in DNA mismatch repair-proficient and -deficient human colon cancer xenografts with 5-iodo-2-pyrimidinone-2'-deoxyribose.
Seo Y; Yan T; Schupp JE; Colussi V; Taylor KL; Kinsella TJ
Clin Cancer Res; 2004 Nov; 10(22):7520-8. PubMed ID: 15569982
[TBL] [Abstract][Full Text] [Related]
7. 5-iodo-2-pyrimidinone-2'-deoxyribose-mediated cytotoxicity and radiosensitization in U87 human glioblastoma xenografts.
Kinsella TJ; Kinsella MT; Seo Y; Berk G
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1254-61. PubMed ID: 17967315
[TBL] [Abstract][Full Text] [Related]
8. IPdR: a novel oral radiosensitizer.
Saif MW; Berk G; Cheng YC; Kinsella TJ
Expert Opin Investig Drugs; 2007 Sep; 16(9):1415-24. PubMed ID: 17714027
[TBL] [Abstract][Full Text] [Related]
9. Phase I and Pharmacology Study of Ropidoxuridine (IPdR) as Prodrug for Iododeoxyuridine-Mediated Tumor Radiosensitization in Advanced GI Cancer Undergoing Radiation.
Kinsella T; Safran H; Wiersma S; DiPetrillo T; Schumacher A; Rosati K; Vatkevich J; Anderson LW; Hill KD; Kunos C; Collins JM
Clin Cancer Res; 2019 Oct; 25(20):6035-6043. PubMed ID: 31337643
[TBL] [Abstract][Full Text] [Related]
10. Conversion of 5-iodo-2-pyrimidinone-2'-deoxyribose to 5-iodo-deoxyuridine by aldehyde oxidase. Implication in hepatotropic drug design.
Chang CN; Doong SL; Cheng YC
Biochem Pharmacol; 1992 May; 43(10):2269-73. PubMed ID: 1599512
[TBL] [Abstract][Full Text] [Related]
11. Toxicology and pharmacokinetic study of orally administered 5-iodo-2-pyrimidinone-2'deoxyribose (IPdR) x 28 days in Fischer-344 rats: impact on the initial clinical phase I trial design of IPdR-mediated radiosensitization.
Kinsella TJ; Kinsella MT; Hong S; Johnson JP; Burback B; Tosca PJ
Cancer Chemother Pharmacol; 2008 Feb; 61(2):323-34. PubMed ID: 17562042
[TBL] [Abstract][Full Text] [Related]
12. In vivo modulation of iododeoxyuridine metabolism and incorporation into cellular DNA by 5'-amino-5'-deoxythymidine in normal mouse tissues and two human colon cancer xenografts.
Kinsella TJ; Glennon MC; Kunugi KA; Lindstrom MJ
Clin Cancer Res; 1996 Jun; 2(6):981-9. PubMed ID: 9816259
[TBL] [Abstract][Full Text] [Related]
13. Implantable biodegradable polymers for IUdR radiosensitization of experimental human malignant glioma.
Williams JA; Dillehay LE; Tabassi K; Sipos E; Fahlman C; Brem H
J Neurooncol; 1997 May; 32(3):181-92. PubMed ID: 9049879
[TBL] [Abstract][Full Text] [Related]
14. Synthetic, implantable polymers for IUdR radiosensitization of experimental human malignant glioma.
Yuan X; Dillehay LE; Williams JR; Williams JA
Cancer Biother Radiopharm; 1999 Jun; 14(3):187-202. PubMed ID: 10850303
[TBL] [Abstract][Full Text] [Related]
15. The potential superiority of bromodeoxyuridine to iododeoxyuridine as a radiation sensitizer in the treatment of colorectal cancer.
Lawrence TS; Davis MA; Maybaum J; Mukhopadhyay SK; Stetson PL; Normolle DP; McKeever PE; Ensminger WD
Cancer Res; 1992 Jul; 52(13):3698-704. PubMed ID: 1617642
[TBL] [Abstract][Full Text] [Related]
16. Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study.
Schulz CA; Mehta MP; Badie B; McGinn CJ; Robins HI; Hayes L; Chappell R; Volkman J; Binger K; Arzoomanian R; Simon K; Alberti D; Feierabend C; Tutsch KD; Kunugi KA; Wilding G; Kinsella TJ
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1107-15. PubMed ID: 15234045
[TBL] [Abstract][Full Text] [Related]
17. Targeted radiosensitisation by pegylated liposome-encapsulated 3', 5'-O-dipalmitoyl 5-iodo-2'-deoxyuridine in a head and neck cancer xenograft model.
Harrington KJ; Syrigos KN; Uster PS; Zetter A; Lewanski CR; Gullick WJ; Vile RG; Stewart JS
Br J Cancer; 2004 Jul; 91(2):366-73. PubMed ID: 15199395
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of intravenous iododeoxyuridine as a clinical radiosensitizer.
Kinsella TJ; Russo A; Mitchell JB; Collins JM; Rowland J; Wright D; Glatstein E
Int J Radiat Oncol Biol Phys; 1985 Nov; 11(11):1941-6. PubMed ID: 2997090
[TBL] [Abstract][Full Text] [Related]
19. Radiolabeled nucleoside analogs in cancer diagnosis and therapy.
Kassis AI; Adelstein SJ; Mariani G
Q J Nucl Med; 1996 Sep; 40(3):301-19. PubMed ID: 8961807
[TBL] [Abstract][Full Text] [Related]
20. First-in-human phase 0 trial of oral 5-iodo-2-pyrimidinone-2'-deoxyribose in patients with advanced malignancies.
Kummar S; Anderson L; Hill K; Majerova E; Allen D; Horneffer Y; Ivy SP; Rubinstein L; Harris P; Doroshow JH; Collins JM
Clin Cancer Res; 2013 Apr; 19(7):1852-7. PubMed ID: 23403637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]